Scarica l'app Stockscreener
19.00
5.28%
-1.06
Dopo l'orario di chiusura:
19.36
0.36
+1.89%
Precedente Chiudi:
$20.06
Aprire:
$19.27
Volume 24 ore:
138.93K
Relative Volume:
0.16
Capitalizzazione di mercato:
$75.73M
Reddito:
-
Utile/perdita netta:
$-24.77M
Rapporto P/E:
-26.03
EPS:
-0.73
Flusso di cassa netto:
$-17.36M
1 W Prestazione:
-18.28%
1M Prestazione:
+156.06%
6M Prestazione:
+103.30%
1 anno Prestazione:
+108.75%
Intervallo 1D:
$18.54
$20.00
Intervallo di 1 settimana:
$18.54
$24.00
Portata 52W:
$4.5601
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Nome
Mink Therapeutics Inc
Settore
Industria
Telefono
212-994-8250
Indirizzo
149 FIFTH AVENUE, NEW YORK
Confronta INKT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
19.00 | 79.95M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Borsa (INKT) Ultime notizie
What analysts say about MiNK Therapeutics Inc. stockExplosive market performance - PrintWeekIndia
MiNK Therapeutics Inc. Stock Analysis and ForecastConsistent triple returns - Autocar Professional
What drives MiNK Therapeutics Inc. stock priceUnprecedented profits - jammulinksnews.com
Is MiNK Therapeutics Inc. a good long term investmentFree Investment Timing Strategies - jammulinksnews.com
(INKT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
How MiNK Therapeutics Inc. stock performs during market volatilityRisk Managed Trading Strategy - Newser
MiNK Therapeutics (NASDAQ:INKT) Upgraded at B. Riley - Defense World
MiNK Therapeutics Announces Clinical Trial Success - MSN
MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress - Oncodaily
MiNK Therapeutics (NASDAQ:INKT) Rating Lowered to “Neutral” at HC Wainwright - Defense World
Mink Therapeutics Shares Slide After Announcing $50 Million Stock Offering - MSN
MiNK Therapeutics (NASDAQ:INKT) Cut to Neutral at HC Wainwright - Defense World
Mink Therapeutics stock tumbles on $50 million stock offering - Investing.com
Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN
What makes MiNK Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser
Why MiNK Therapeutics Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
MiNK Therapeutics stock rating downgraded to Neutral by H.C. Wainwright - Investing.com Canada
MiNK Therapeutics Plummets 29%—What’s Driving the Sell-Off? - AInvest
MiNK Therapeutics Plummets 28.59% — What’s Driving the Sell-Off? - AInvest
Mink Therapeutics stock tumbles on $50 million stock offering By Investing.com - Investing.com Nigeria
MiNK Therapeutics publishes research on CAR-iNKT cell therapy By Investing.com - Investing.com South Africa
MiNK Therapeutics enters $50 million at-the-market sales agreement with B. Riley Securities By Investing.com - Investing.com South Africa
MiNK Therapeutics enters $50 million at-the-market sales agreement with B. Riley Securities - Investing.com Canada
MiNK Therapeutics Publishes Peer-Reviewed Article Highlighting Innovations in CAR-iNKT Cell Therapies for Solid Tumors - Nasdaq
MiNK Therapeutics Announces Frontiers in Immunology - GlobeNewswire
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy - TradingView
Revolutionary iNKT Cell Therapy Achieves 2-Year Complete Remission in Treatment-Resistant Cancer - Stock Titan
MiNK Therapeutics tumbles after $50 mln stock offering filing - TradingView
INKT’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
MiNK Therapeutics Enters $50M Sales Agreement with B. Riley - TipRanks
MiNK Therapeutics Plunges 24.87% After William Blair Downgrade - AInvest
INKT sets up $50M ATM with B. Riley, adds financing flexibility | INKT SEC FilingForm 8-K - Stock Titan
Mink Therapeutics Inc Azioni (INKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):